Journey Medical FY2027 EPS Estimate Decreased by B. Riley

Journey Medical Co. (NASDAQ:DERM) – Equities researchers at B. Riley lowered their FY2027 earnings estimates for shares of Journey Medical in a report issued on Thursday, March 27th. B. Riley analyst K. Patel now anticipates that the company will post earnings of $0.31 per share for the year, down from their previous forecast of $0.39. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share.

Journey Medical (NASDAQ:DERM) last issued its earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.30. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The firm had revenue of $14.30 million for the quarter, compared to analysts’ expectations of $14.21 million.

Separately, Alliance Global Partners reissued a “buy” rating on shares of Journey Medical in a report on Thursday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $9.67.

Journey Medical Stock Performance

NASDAQ:DERM opened at $5.90 on Monday. The company has a market cap of $123.25 million, a price-to-earnings ratio of -6.28 and a beta of 0.97. Journey Medical has a 1 year low of $3.20 and a 1 year high of $6.89. The stock’s 50 day simple moving average is $5.14 and its two-hundred day simple moving average is $5.18. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03.

Institutional Investors Weigh In On Journey Medical

A number of institutional investors and hedge funds have recently modified their holdings of DERM. Kovitz Investment Group Partners LLC purchased a new position in Journey Medical in the 3rd quarter worth about $66,000. Cetera Investment Advisers boosted its position in Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after purchasing an additional 2,478 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Journey Medical in the 4th quarter worth approximately $80,000. Citadel Advisors LLC purchased a new position in Journey Medical in the fourth quarter worth $174,000. Finally, Geode Capital Management LLC increased its position in Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after buying an additional 12,882 shares in the last quarter. 7.25% of the stock is owned by institutional investors.

Insider Transactions at Journey Medical

In related news, CEO Claude Maraoui sold 14,905 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.01, for a total value of $74,674.05. Following the sale, the chief executive officer now directly owns 2,052,418 shares of the company’s stock, valued at $10,282,614.18. This represents a 0.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders sold 105,831 shares of company stock worth $536,622. 13.16% of the stock is currently owned by company insiders.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.